By enhancing the bioavailability and stability of ABCG2 inhibitors, this research contributes to the ongoing efforts to develop more effective strategies for combating MDR in breast cancer and other chemoresistant malignancies. The gene discussed is ABCG2; the disease is breast carcinoma.